Specific antibodies induced by inactivated parapoxvirus ovis potently enhance oxidative burst in canine blood polymorphonuclear leukocytes and monocytes.
We have recently shown that inactivated parapoxvirus ovis (iPPVO) effectively stimulates canine blood phagocytes. However, a potential link between innate and adaptive immunity induced by iPPVO remained open. The objective of this study was to define the effects of repeated iPPVO treatment of dogs to evaluate (i) iPPVO-specific antibody production, and (ii) modulation of iPPVO-induced oxidative burst by anti-iPPVO antibodies. Serum analysis of dogs treated repeatedly with iPPVO (Zylexis) showed transient production of non-neutralising iPPVO-specific IgG. There was a correlation between iPPVO-specific IgG levels and enhanced oxidative burst rates in vitro upon transfer of immune sera. Even four years after Zylexis treatment considerably stronger oxidative burst rates in response to iPPVO were observed in monocytes and PMN, whereas only moderate burst rates were detected in monocytes, but not in PMN, from dogs treated with a placebo. Depletion of serum IgG by protein A-sepharose or by parapoxvirus ovis coupled to sepharose abolished the increase of oxidative burst responses and resulted in burst rates similar to blood leukocytes from control dogs. However, uptake of viral particles was found to be independent of iPPVO-specific IgG and restricted to cells with dendritic and monocytic morphology. These data demonstrate that non-neutralising iPPVO-specific IgG is produced during treatment with Zylexis. Moreover, for the first time the interaction of iPPVO with antibodies is shown to enhance oxidative burst.
Schütze
Nicole
N
Institute of Immunology, College of Veterinary Medicine, University of Leipzig, An den Tierkliniken, 11, 04103 Leipzig, Germany.
Raue
Rüdiger
R
Büttner
Mathias
M
Köhler
Gabriele
G
McInnes
Colin J
CJ
Alber
Gottfried
G
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000276:immunology*; D002417:Cattle; D002460:Cell Line; D002478:Cells, Cultured; D004285:Dogs; D007106:Immune Sera / Q000276:immunology; D007113:Immunity, Innate / Q000276:immunology; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology*; D018157:Parapoxvirus / Q000276:immunology*; D011213:Poxviridae Infections / Q000276:immunology / Q000662:veterinary* / Q000821:virology; D016897:Respiratory Burst / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007106:Immune Sera; D007074:Immunoglobulin G; D014765:Viral Vaccines